ArticleJournal of gastrointestinal oncology2025
Construction of conditional survival nomograms for metastatic early onset colon cancer patients.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Conditional survival (CS), which factors in the postoperative survival duration of the patient, provides supplementary prognostic insights. The principal objectives of this study were to evaluate CS in metastatic early onset colon cancer (mEO-CC) patients and to construct innovative nomograms designed to predict the probability of CS, thus advancing the precision of prognostic modeling in this distinct clinical context. However, CS tools tailored to mEO-CC remain limited. Methods: The data of patients diagnosed with mEO-CC between 2010 and 2019 from the Surveillance, Epidemiology, and End Results (SEER) database were included in our study. CS was defined as the probability of surviving for an additional number of years after already surviving for a specific number of years since diagnosis. Nomograms were constructed to predict the probability of conditional overall survival (OS) and cancer-specific survival (CSS) respectively. Results: A total of 1,988 patients with mEO-CC were included in this study. The 5-year OS and CSS after surgery increased gradually with additional survival time. The univariate and multivariate Cox regression analyses identified a right-colon tumor, poorly differentiated tumor, mucinous/signet ring tumors, a late tumor stage, a high lymph node ratio (LNR), an elevated carcinoembryonic antigen (CEA) level, perineural invasion, and bone, liver or lung metastasis as independent risk factors for OS and CSS. Two nomograms with considerable predictive ability were successfully established for the prediction of conditional 5-year OS [area under the curve (AUC) =0.765] and CSS (AUC =0.761). Conclusions: The probability of achieving 5-year OS and 5-year CSS in mEO-CC patients increased based on the years already survived. Nomograms that consider survival time are more reliable and informative in terms of prognosis prediction in patients with mEO-CC. These time-adjusted estimates may facilitate risk communication and follow-up planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.